Jan. 13 at 11:12 AM
$AVDL $21.50
Was Legacy Core Holding
ADDED 5X POSITION at
$7.61
https://stocktwits.com/G101SPM/message/606248004
BRIEF: Avadel Pharmaceuticals announces that Avadel Shareholders approve the proposed acquisition by Alkermes
note:
$ALKS Alkermes agreed to pay
$21.00 per share in cash plus a Contingent Value Right (CVR) of
$1.50 per share.
Alkermes acquired Avadel primarily to accelerate its entry into the commercial sleep medicine market and strengthen its existing neuroscience pipeline. Key strategic reasons include:
Acquiring Lumryz™: Alkermes gains access to Lumryz™, the first and only once-at-bedtime oxybate treatment for narcolepsy. This drug is a key growth driver, with projected sales of over
$265 million in 2025.
Commercial Infrastructure: Alkermes will utilize Avadel’s established sales force and commercial operations in the sleep disorder space to support the future launch of its own development candidate, alixorexton.
Synergy with Pipeline: The deal is seen as highly complementary; while Lumryz™ promotes sleep, Alkermes' in-house candidates (like alixorexton) target wake-promotion, potentially allowing for combined therapeutic strategies.
Financial Growth: The acquisition is expected to be immediately accretive, enhancing Alkermes' revenue growth and profitability.
^^^ Planning to take position in
$ALKS upon improved SPM tag.
